English | Spanish
ecancer
Supporting oncology professionals through education
Login Register

The content on this site is intended for healthcare professionals only

  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

News

  • Latest news
  • Sign up for news alerts
  • Submit your news

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Journal information

  • Journal home
  • Charges
  • Editorial board
  • Founding editors
  • Editor-in-chief
  • Contact us

Author information

  • Submit article
  • Author guidelines
  • Editorial policies
  • Copyright information
  • Why publish with us

Reviewer information

  • Reviewer guidelines

Memberships

Open Access Scholarly Publishers Association Crossref Healthcare Information For All Commitee On Publication Ethics

Videos

  • Recent videos
  • Sign up

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Conferences

  • Latest conferences
  • Sign up for latest coverage
  • Submit your event

About ecancer

  • About ecancer
  • Our founders
  • Funding statement
  • Contact us
  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology
+ -
Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

ecancer and the City Cancer Challenge have formed an educational collaboration. Learners who are part of the City Cancer Challenge's project can access additional education provided by them.

Please login or register. Then you can use this button to confirm you are part of this project.
Register for free Already have an account? Login
Videos [3923]
News [11395]
Articles [47]
Editorials [10]
Conferences [197]
elearning [4]
Pathologic complete response rates improved with the neoadjuvant and adjuvant...
Prof Peter Schmid - St Bartholomew's Hospital London, London, UK
Pathologic complete response rates improved with the neoadjuvant and adjuvant treatment of pembrolizumab in TNBC patients ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )
18 Dec 2019
Combining atezolizumab to neoadjuvant chemotherapy does not improve pathologic...
Dr Luca Gianni - San Raffaele Hospital, Milan, Italy
Combining atezolizumab to neoadjuvant chemotherapy does not improve pathologic complete response rates for TNBC patients ( Dr Luca Gianni -  San Raffaele Hospital, Milan, Italy )
18 Dec 2019
Breast cancer prevention in high-risk post-menopausal women
Prof Jack Cuzick - Queen Mary University of London, London, UK
Breast cancer prevention in high-risk post-menopausal women ( Prof Jack Cuzick - Queen Mary University of London, London, UK )
18 Dec 2019
Accelerated partial breast irradiation versus whole breast irradiation in...
Dr Icro Meattini - Univerity of Florence, Florence, Italy
Accelerated partial breast irradiation versus whole breast irradiation in patients with early breast cancer ( Dr Icro Meattini - Univerity of Florence, Florence, Italy )
18 Dec 2019
Evaluating the combination of atezolizumab with neoadjuvant chemotherapy for...
Dr Luca Gianni - San Raffaele Hospital, Milan, Italy
Evaluating the combination of atezolizumab with neoadjuvant chemotherapy for the treatment of triple-negative breast cancer ( Dr Luca Gianni -  San Raffaele Hospital, Milan, Italy )
18 Dec 2019
Preventative effects of anastrozole in post-menopausal women who are at high...
Prof Jack Cuzick - Queen Mary University of London, London, UK
Preventative effects of anastrozole in post-menopausal women who are at high-risk for developing breast cancer ( Prof Jack Cuzick - Queen Mary University of London, London, UK )
18 Dec 2019
How effective is accelerated partial breast irradiation in patients with early...
Dr Icro Meattini - Univerity of Florence, Florence, Italy
How effective is accelerated partial breast irradiation in patients with early breast cancer? ( Dr Icro Meattini - Univerity of Florence, Florence, Italy )
18 Dec 2019
Predicting disease recurrence in patients with early triple-negative breast...
Dr Milan Radovich - Indiana University Melvin and Bren Simon Cancer Center...
Predicting disease recurrence in patients with early triple-negative breast cancer using circulating tumour DNA ( Dr Milan Radovich - Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, USA )
18 Dec 2019
The emerging role of immunotherapy for the treatment of early and advanced...
Dr Rita Nanda - UChicago Medicine, Chicago, USA
The emerging role of immunotherapy for the treatment of early and advanced breast cancer ( Dr Rita Nanda - UChicago Medicine, Chicago, USA )
18 Dec 2019
APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with...
Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium
APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with operable HER2-positive early breast cancer ( Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium )
18 Dec 2019
Breast cancer incidence in post-menopausal women: Long-term influence of...
Prof Rowan Chlebowski - City of Hope National Medical Center, Duarte, USA
Breast cancer incidence in post-menopausal women: Long-term influence of oestrogen plus progestin versus oestrogen alone ( Prof Rowan Chlebowski - City of Hope National Medical Center, Duarte, USA )
18 Dec 2019
Could trastuzumab deruxtecan become the new standard of care for pretreated...
Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA
Could trastuzumab deruxtecan become the new standard of care for pretreated HER2-positive breast cancer patients? ( Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA )
18 Dec 2019
<1...149150151152153...327>

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation

  • Contact
  • Projects
  • Cookie Policy
  • Terms of Use
  • Desktop Site
  • Privacy Policy
© 2025 ecancer, all rights reserved
UK registered charity number: 1176307
Back to Top